Latest Audit News

Count has reported a strong start to FY2027, with first-quarter revenue up 23.2%, underlying EBITA up 66.6% and funds under management reaching $6.7 billion. The group is also pursuing a 30% stake in Brisbane accounting and advice firm Apiary, although the purchase price remains undisclosed and completion requires ACCC approval.

Battery Age Minerals advanced its Bleiberg germanium permits and expanded Falcon Lake to about 60 km², but its cash position now covers an estimated 1.34 quarters of funding. Initial Apex fieldwork also failed to confirm the remote-sensing anomalies that had defined the Utah targets.

RemSense reported stronger customer receipts, an 89% rise in invoiced services and further expansion across Woodside-operated assets in the September quarter. The progress comes with negative operating cash flow and a reported 2.32 quarters of funding, keeping execution and cash conversion firmly in focus.

Truscott Mining is preparing a 3,000 to 4,000 metre diamond drilling program at its Westminster gold project, with drilling intended to support a JORC 2012 resource estimate. The ASX-listed explorer ended September with A$626,000 in cash and reported estimated funding for 3.62 quarters, including an unused facility.

Hallenstein Glasson Holdings delivered a sharply stronger FY2026, with sales up 19.6% to NZ$563.0 million and net profit after tax rising 49.9% to NZ$59.2 million. The retailer enters FY2027 with strong early sales momentum, although management warns the opening 18.4% growth rate is unlikely to last.

Yowie Group has entered FY27 with US$71,000 in cash, a 35% drop in US gross sales and a fully drawn A$4 million working capital facility. The confectionery maker is pursuing an approximately A$6 million two-tranche capital raising while its ASX quotation remains suspended.

Caravel Minerals is moving its 100%-owned Caravel Copper Project towards a Definitive Feasibility Study due in the fourth quarter, but the annual report also flags a material uncertainty over its ability to continue as a going concern. The company remains pre-revenue, with approvals, project finance and key commercial arrangements still incomplete.

Chimeric Therapeutics has stopped enrolment and dosing in its CHM-2101 CAR-T trial after a safety review found the highest dose unsafe. With $1.35 million in cash, suspended securities and uncertain creditor negotiations, the company is now pursuing a possible recapitalisation while preserving a preclinical CDH17 pathway.

Mindax ended FY2026 with just A$83,116 in cash and a A$2.49 million loss before tax, prompting its auditor to highlight material uncertainty over the company’s ability to continue as a going concern. Post-year-end funding has lifted cash to A$4.079 million, although much of that support remains tied to convertible debt and approvals.

Transmetro Corporation (ASX:TCO) delivered a 50% increase in FY2026 net profit to A$4.49 million, while cash rose to A$13.94 million and the fully franked dividend increased to 6 cents per share. The debt-free hotel operator is preparing to open Metro Hotel Martin Place Sydney and support a major refurbishment of its 220-room Marlow property.

American Rare Earths has moved Halleck Creek closer to development, expanding the proposed Cowboy State Mine, completing 18 feasibility-stage drill holes and beginning pilot plant processing. But with A$11.0 million in cash and an estimated 1.44 quarters of funding at current outgoings, the next phase will likely require fresh capital or another funding source.

Mesoblast has posted a 44% rise in first-quarter Ryoncil revenue to US$28 million while sharply reducing operating cash use. The biotechnology company also completed treatment in its 350-patient chronic low back pain trial and received FDA confirmation that a heart-failure BLA filing may proceed.